The clinical pharmacology of alkylating agents in high-dose chemotherapy

A. D. Huitema; K. D. Smits; R. A. Mathôt; J. H. Schellens; S. Rodenhuis; J. H. Beijnen

doi:https://doi.org/10.1097/00001813-200008000-00002

The clinical pharmacology of alkylating agents in high-dose chemotherapy

A. D. Huitema, K. D. Smits, R. A. Mathôt, J. H. Schellens, S. Rodenhuis, J. H. Beijnen

Other Departments

Research output: Contribution to journal › Review article › Academic › peer-review

40 Citations (Scopus)

Abstract

Alkylating agents are widely used in high-dose chemotherapy regimens in combination with hematological support. Knowledge about the pharmacokinetics and pharmacodynamics of these agents administered in high doses is critical for the safe and efficient use of these regimens. The aim of this review is to summarize the clinical pharmacology of the alkylating agents (including the platinum compounds) in high-dose chemotherapy. Differences between conventional and high doses will be discussed

Original language	English
Pages (from-to)	515-533
Journal	Anti-Cancer Drugs
Volume	11
Issue number	7
DOIs	https://doi.org/10.1097/00001813-200008000-00002
Publication status	Published - 2000

Access to Document

https://doi.org/10.1097/00001813-200008000-00002

Cite this

@article{b9829ea902584077911a78c88a02b642,

title = "The clinical pharmacology of alkylating agents in high-dose chemotherapy",

abstract = "Alkylating agents are widely used in high-dose chemotherapy regimens in combination with hematological support. Knowledge about the pharmacokinetics and pharmacodynamics of these agents administered in high doses is critical for the safe and efficient use of these regimens. The aim of this review is to summarize the clinical pharmacology of the alkylating agents (including the platinum compounds) in high-dose chemotherapy. Differences between conventional and high doses will be discussed",

author = "Huitema, {A. D.} and Smits, {K. D.} and Math{\^o}t, {R. A.} and Schellens, {J. H.} and S. Rodenhuis and Beijnen, {J. H.}",

year = "2000",

doi = "https://doi.org/10.1097/00001813-200008000-00002",

language = "English",

volume = "11",

pages = "515--533",

journal = "Anti-Cancer Drugs",

issn = "0959-4973",

publisher = "Lippincott Williams and Wilkins",

number = "7",

}

TY - JOUR

T1 - The clinical pharmacology of alkylating agents in high-dose chemotherapy

AU - Huitema, A. D.

AU - Smits, K. D.

AU - Mathôt, R. A.

AU - Schellens, J. H.

AU - Rodenhuis, S.

AU - Beijnen, J. H.

PY - 2000

Y1 - 2000

N2 - Alkylating agents are widely used in high-dose chemotherapy regimens in combination with hematological support. Knowledge about the pharmacokinetics and pharmacodynamics of these agents administered in high doses is critical for the safe and efficient use of these regimens. The aim of this review is to summarize the clinical pharmacology of the alkylating agents (including the platinum compounds) in high-dose chemotherapy. Differences between conventional and high doses will be discussed

AB - Alkylating agents are widely used in high-dose chemotherapy regimens in combination with hematological support. Knowledge about the pharmacokinetics and pharmacodynamics of these agents administered in high doses is critical for the safe and efficient use of these regimens. The aim of this review is to summarize the clinical pharmacology of the alkylating agents (including the platinum compounds) in high-dose chemotherapy. Differences between conventional and high doses will be discussed

U2 - https://doi.org/10.1097/00001813-200008000-00002

DO - https://doi.org/10.1097/00001813-200008000-00002

M3 - Review article

C2 - 11036954

SN - 0959-4973

VL - 11

SP - 515

EP - 533

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

IS - 7

ER -